SEC Form 4 · accession 0001918845-26-000022
Avalo Therapeutics, Inc. · AVTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mittie Doyle
Officer — Chief Medical Officer
Period of report
Jun 30, 2026
Accepted (ET)
Jul 2, 2026 · 4:05 pm EDT
Rule 10b5-1 plan
yes — trade under a plan
Issuer CIK
0001534120
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 30, 2026 | M | 2,875 | $12.65 | A | 54,651 | D | |
| Common Stock | Jun 30, 2026 | M | 1,779 | $8.04 | A | 56,430 | D | |
| Common Stock | Jun 30, 2026 | S | 4,654 | $20.00 | D | 51,776 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $12.65 | Jun 30, 2026 | M | 2,875 | D | — | Jul 15, 2034 | Common Stock | 2,875 | 125,750 | D |
| Stock Option (Right to Buy)F3 | $8.04 | Jun 30, 2026 | M | 1,779 | D | — | Jan 28, 2035 | Common Stock | 1,779 | 115,092 | D |
Explanation of responses
- F1The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 13, 2025.
- F2The stock option vests twenty-five percent (25%) on July 15, 2025 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.
- F3The stock option vests twenty-five percent (25%) on January 28, 2026 and the remainder will vest in equal monthly installments over the following three (3) years, subject to the Reporting Person's continued service on each such vesting date.